sciencefront

Rosiglitazone (Avandia) is in the news because of the increased incidence of myocardial infarction and heart failure. FDA has stopped short of issuing a recall of the medication. I am a physician with special interest in diabetic heart disease. My understanding of the current situation is that each case should be reviewed individually. You in partnership with your physician should decide how important rosiglitazone is for your diabetes control. If the risks outweigh the benefits, obviously should be discontinued. I have written a short article in my diabetic heart disease blog. please read here. Hope you find it useful.